BIBLIOS

  Sistema de Gestão de Referências Bibliográficas de Ciências

Modo Visitante (Login)
Need help?


Voltar

Detalhes Referência

Tipo
Artigos em Revista

Tipo de Documento
Artigo Completo

Título
Anti-cancer activity and in vitro to in vivo mechanistic recapitulation of novel ruthenium-based metallodrugs in the zebrafish model

Participantes na publicação
B.F Karas (Author)
RUTGERS UNIVERSITY
J.M Hotz (Author)
RUTGERS UNIVERSITY
B.M Gural (Author)
RUTGERS UNIVERSITY
K.R Terez (Author)
RUTGERS UNIVERSITY
V.L DiBona (Author)
RUTGERS UNIVERSITY
L. Côrte-Real (Author)
FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA
CQE
A. Valente (Author)
FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA
CQE
B.T Buckley (Author)
RUTGERS UNIVERSITY
K.R Cooper (Author)
RUTGERS UNIVERSITY

Resumo
Ruthenium is popular as a metal core for chemotherapeutics, due to versatile molecular coordination. Because new metallodrugs are synthesized at high rates, our studies included assays in zebrafish to expedite the initial evaluation as anticancer agents. Here we evaluated novel metallodrugs (PMC79 and LCR134), and cisplatin, a widely used platinum-based chemotherapeutic. We hypothesized that this model could characterize anticancer properties and recapitulate previous in vitro results in vivo. Our findings suggest anticancer properties of PMC79 and LCR134 were similar with less toxicity than cisplatin. Exposures from 24 to 72 h at or below the LOAELs of PMC79 and LCR134 (3.9 µM and 13.5 µm, respectively), impaired blood vessel development and tailfin regeneration. Blood vessel examination through live imaging of larvae revealed distinct regional antiangiogenic impacts. The significant decrease in gene expression of the VEGF-HIF pathway and beta-actin could explain the morphological effects observed in the whole organism following exposure. Tailfin amputation in larvae exposed to PMC79 or LCR134 inhibited tissue regrowth and cell division, but did not impact normal cell proliferation unlike cisplatin. This suggests Ru drugs may be more selective in targeting cancerous cells than cisplatin. Additionally, in vitro mechanisms were confirmed. PMC79 disrupted cytoskeleton formation in larvae and P-glycoprotein transporters in vivo was inhibited at low doses which could limit off-target effects of chemotherapeutics. Our results demonstrate the value for using the zebrafish in metallodrug research to evaluate mechanisms and off-target effects. In light of the findings reported in this article, future investigation of PMC79 and LCR134 are warranted in higher vertebrate models.

Data de Publicação
2021-04-03

Instituição
FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA

Suporte
Toxicological Sciences

Identificadores da Publicação

Identificadores do Documento
DOI - https://doi.org/10.1093/toxsci/kfab041

Identificadores de Qualidade
SCIMAGO Q1 (2020) - 1.352 - Toxicology


Exportar referência

APA
B.F Karas, J.M Hotz, B.M Gural, K.R Terez, V.L DiBona, L. Côrte-Real, A. Valente, B.T Buckley, K.R Cooper, (2021). Anti-cancer activity and in vitro to in vivo mechanistic recapitulation of novel ruthenium-based metallodrugs in the zebrafish model. Toxicological Sciences,

IEEE
B.F Karas, J.M Hotz, B.M Gural, K.R Terez, V.L DiBona, L. Côrte-Real, A. Valente, B.T Buckley, K.R Cooper, "Anti-cancer activity and in vitro to in vivo mechanistic recapitulation of novel ruthenium-based metallodrugs in the zebrafish model" in Toxicological Sciences, 2021. 10.1093/toxsci/kfab041

BIBTEX
@article{52018, author = {B.F Karas and J.M Hotz and B.M Gural and K.R Terez and V.L DiBona and L. Côrte-Real and A. Valente and B.T Buckley and K.R Cooper}, title = {Anti-cancer activity and in vitro to in vivo mechanistic recapitulation of novel ruthenium-based metallodrugs in the zebrafish model}, journal = {Toxicological Sciences}, year = 2021, }